关注宫缩抑制剂使用中的安全问题  

Pay attention to the safety of tocolytics in clinic

作　　者：张力 刘丹[2] 张伶俐[2] Zhang Li;Liu Dan;Zhang Lingli(Department of Obstetrics and Gynecology,Key Laboratory of Birth Defects and Related Diseases of Women and Children,West China Second University Hospital,Sichuan University,Chengdu 610041,China;Depart‑ment of Pharmacy,Evidence‑Based,Pharmacy Center,Key Laboratory of Birth Defects and Related Diseases of Women and Children,West China Second University Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西第二医院妇产科/出生缺陷与相关妇儿疾病教育部重点实验室,成都610041 [2]四川大学华西第二医院药学部/四川大学华西第二医院循证药学中心/出生缺陷与相关妇儿疾病教育部重点实验室,成都610041

出　　处：《药物不良反应杂志》2023年第7期385-388,共4页Adverse Drug Reactions Journal

摘　　要：早产是5岁以下儿童的主要死亡原因之一。宫缩抑制剂可延长妊娠时间,是治疗早产的重要措施之一。然而在临床使用中,药物的使用指征、疗效监测、治疗时间和安全性监测仍存在许多问题。本文基于早产相关指南,结合临床实践,对早产患者宫缩抑制剂使用中的一些问题进行评述,为早产管理提供帮助。Premature birth is one of the leading causes of death in children under 5 years of age.Tocolytic inhibitors can prolong pregnancy time and are one of the important treatment measures for preterm birth.However,there are still many problems in the indications,efficacy monitoring,course of treatment,and safety monitoring of drugs in clinical use.Based on the relevant guidelines for preterm birth and in combina‑tion with the clinical practice,this paper reviews some problems in the use of tocolytics in preterm labor,so as to provide help for the management of preterm birth.

关 键 词：早产 宫缩抑制剂 保胎 安全性 

分 类 号：R714.21[医药卫生—妇产科学]